SYK stock sentiment todayStryker Corporation
Sentiment verdict
Gossip first, financials second — HOT at 88% confidence.
Last updated · cached analysis, refreshes periodically
SYK
Stryker CorporationA best-in-class medical med-tech compounder benefiting from a massive backlog in elective surgeries and a dominant robotic surgery ecosystem.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for SYK. Not financial advice.
Price · last 12 months
Gossip
The prevailing narrative is centered on 'volume recovery.' Following pandemic delays, there is a sustained surge in orthopedic procedures. Investors are also fixated on the Mako robotic platform's ecosystem, which creates high switching costs and recurring revenue.
- ·Surgical volume recovery
- ·Mako robotic platform expansion into spine and shoulder
- ·Strong hospital CAPEX spending
- ·Consistent earnings beats
Financial
Stryker boasts industry-leading organic growth (often high single digits) and aggressive margin expansion targets. While it carries a premium valuation, its historical ability to integrate acquisitions (like Wright Medical) justifies the 'quality' multiple.
- ·Consistent 8-10% organic sales growth
- ·Operating margins trending toward 25-26%
- ·Solid Free Cash Flow generation
- ·Premium Forward P/E (~30x) vs historical average
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $217.5M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High valuation leaves little room for earnings misses
- ·Potential slowdown in hospital capital budgets
- ·Regulatory scrutiny on large-scale M&A
Peer temperature
How direct competitors stack up against SYK right now.
- NEUTRALZBHZimmer Biomet
COLDER — lower valuation but significantly slower organic growth and less diversified product portfolio compared to SYK.
See full analysis → - COLDMDTMedtronic
COLDER — struggling with legacy supply chain issues and inconsistent execution despite a broader diversified base.
See full analysis → - HOTBSXBoston Scientific
HOTTER — currently enjoying a massive valuation tailwind and higher growth rates due to their dominant position in Electrophysiology (Farapulse).
See full analysis →
- SYK-6.1%
- ZBH+3.9%
- MDT+4.2%
- BSX+1.7%
Analyst price target
Consensus average of 26 analysts · median 390.00
Source: StockAnalysis.com · updated 2026-08-27
AI-generated analysis for informational purposes only. Not financial advice.